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Background and aims: Familial hypercholesterolaemia (FH) is an autosomal dominant lipoprotein dis-
order characterized by significant elevation of low-density lipoprotein cholesterol (LDL-C) and markedly
increased risk of premature cardiovascular disease (CVD). Because of the very high coronary artery
disease risk associated with this condition, the prevalence of FH among patients admitted for CVD
outmatches many times the prevalence in the general population. Awareness of this disease is crucial for
recognizing FH in the aftermath of a hospitalization of a patient with CVD, and also represents a unique
opportunity to identify relatives of the index patient, who are unaware they have FH. This article aims to
describe a feasible strategy to facilitate the detection and management of FH among patients hospitalized
for CVD.
Methods: A multidisciplinary national panel of lipidologists, cardiologists, endocrinologists and cardio-
geneticists developed a three-step diagnostic algorithm, each step including three key aspects of diag-
nosis, treatment and family care.
Results: A sequence of tasks was generated, starting with the process of suspecting FH amongst affected
patients admitted for CVD, treating them to LDL-C target, finally culminating in extensive cascade-
screening for FH in their family. Conceptually, the pathway is broken down into 3 phases to provide
the treating physicians with a time-efficient chain of priorities.
Conclusions: We emphasize the need for optimal collaboration between the various actors, starting with
a "vigilant doctor" who actively develops the capability or framework to recognize potential FH patients,
continuing with an "FH specialist", and finally involving the patient himself as ”FH ambassador” to
approach his/her family and facilitate cascade screening and subsequent treatment of relatives.
© 2018 Elsevier B.V. All rights reserved.1. Introduction
FH remains under-diagnosed and under-treated worldwide [1].
Up to 2013 in Belgium, only a fraction of HeFH carriers have been
genetically characterized [2e8]. Many FH patients continue to
suffer from early-onset cardiac complications before being diag-
nosed [9]. Because of the very high coronary risk associated with
this disease, the prevalence of FH in patients admitted in coronary
care units (CCU) outmatches more than 10 times the frequency
observed in the general population (1/300) [10]. In the EUROASPIRE
IV study [9], up to 8% of adults hospitalized for acute coronary
syndrome (ACS) had clinical criteria compatible with potential FH.
The probability of having FH was even greater in women (11%) and
in younger patients (15% in those< 60 years). Even if this is an
unfortunate reality, the hospitalization of such patients for CVD is a
unique opportunity to initiate the first step of FH screening. The
present paper summarizes the recommendations based on current
evidence and guidelines (2 [11,12]) from a consensus panel
composed of Belgian cardiologists, endocrinologists, lipidologists
and cardiogeneticists to better organize the practice of identifying
and managing FH patients following acute admission to CCU.2. Materials and methods
OD and ER prepared a series of questions intended to achieve a
consensus about a number of basic principles and to examine the
feasibility and practicality of various actions to take in order to
facilitate the suspicion of FH, the confirmation of the diagnosis of
FH, the prescription of an appropriate treatment, and the initiation
of family screening. A panel of national experts composed of lip-
idologists, cardiologists, endocrinologists and cardiogeneticists
examined the current evidence and guidelines and discussed the
possible organization of FH management in their local clinics. Af-
terwards, OD and ER provided a first draft which was then
distributed (2 cycle of reviewing) amongst the other co-authors to
receive their comments, suggestions and the final agreement on the
paper content.3. Results
3.1. Basic principles
Briefly, the management of FH implies the ability to suspect FH
amongst admitted patients, to adequately control their LDL-C level
and, in case of confirmed FH, to propose cascade screening for FH in
the patient's family. To reach such objectives, we developed an
algorithm that splits each of the processes of diagnosis (“DI-
AGNOSE”), therapeutic management (“TREAT”) and family
screening (“FAMILY CARE”) of FH into three phases named “ALERT”,
“CONFIRM” and “EXTEND” (Fig. 1). The idea of breaking down these
processes into 3 phases is to provide doctors with a blueprint of
what needs to be prioritized during each stage for the 3 processes.
It involves the efforts of several stakeholders, starting with a
“vigilant doctor” who suspects potential FH patients, then the
expertise of an “FH specialist” and later on, the involvement of the
patient him/herself as an ”FH ambassador”.
Since FH is a very specific and time-consuming condition to
manage, a cardiologist, endocrinologist or general internist with a
dedicated interest and time for FH (the “FH specialist”) should be
identified in each hospital, ideally assisted by a trained nurse (to
educate and contact relatives for family screening) and a geneticist
(to demonstrate causality of ambiguous genetic variants). Like a
“diabetes clinic”, a “FH clinic” should be organized to provide state-
of-the-art care for FH patients and their family. The general prac-
titioner also has a role in encouraging patients' adherence to lipid-
lowering drugs (LLD), and helping to perform cascade screening as
extensively as possible (See Fig. 1).
The collaboration of the patient is central to approaching and
motivating his/her family members and facilitating cascade
screening. He/she should therefore be fully informed on the he-
reditary nature of his/her hypercholesterolaemia (especially when
FH is confirmed) and be taught how to raise awareness in the family
about the necessity to perform a cholesterol test. This may be
facilitated by providing informational material on FH or referring to
the website of the national patient's association for FH (www.
belchol.be in Belgium).
Fig. 1. Algorithm of diagnosis (“DIAGNOSE”), therapeutic management (“CORRECT LDL 70”) and family screening promotion (“FAMILY SCREEN”) of familial hypercholesterolaemia.
O.S. Descamps et al. / Atherosclerosis 277 (2018) 369e376 3713.2. Diagnose
3.2.1. Phase 1. “ALERT
In a CCU, the first and major step of identifying a potential FH
carrier must be integrated amongst other priorities, during a short
stay and into the flow of all admitted patients. In such an acute and
busy setting, it may not be appropriate to promote the use of an
additional score specific to non-urgent FH diagnosis. Therefore, the
panel recommends raising suspicion based on 2 simple warning
signs for FH which should be checked in all patients admitted for
incident CVD.
1. LDL cholesterol level (LDL-C) above 190mg/dl without treat-
ment, or above 130mg/dL on LLD(s) in a blood sampling per-
formed as soon as possible after admission (not necessarily in
the fasting state); and
2. Age of onset of the acute coronary syndrome (ACS) or any other
atherosclerotic disease before 65 years.
LDL-C level is little affected by the postprandial state [13] or by
ACS-induced systemic inflammation, an habitual LDL-C lowering
effect (10e15%) being maximal after 4 days [14,15]. The cut-off of
190mg/dL is the limit proposed by guidelines for suspecting FH (1).
In patients currently treated with LLD, the inferior limit is expected
to be around 130mg/dL (taking into account the most commonly-
used statins, simvastatin 20 or atorvastatin 10mg, which lower
LDL-C by an average 35%), but in case of more intensive LLD,
baseline LDL-C may be calculated using the correction factor spe-
cific of the ongoing LLD [16]. The panel considers a unique age cut-
off for both sexes to facilitate awareness and set at an older age than
usual to be more sensitive. The definition of premature familyhistory in the DLCN is indeed far too restrictive for screening at this
stage in such an environment.
These criteria, given as indication, must be nuanced using
common clinical sense. For example, the age cut-off may be
increased in the presence of conditions decreasing the likeliness of
an earlier CV event: absence of any other CV risk factors, healthy
lifestyle, longer history of LLD use. The LDL-C cut-offs may also be
lowered (>155mg/dL without previous LLD, and >120mg/dL with
LLD) in the presence of strong pathognomonic signs suggesting FH:
very early (<50 years) personal CVD disease, history of premature
CVD and/or hypercholesterolaemia in numerous relatives, tendon
xanthomas or corneal arcus before 45 years.
In a preliminary observation of 144 admissions for ACS in one
CCU (O.V.C., personal observation), it was observed that only 2% of
patients met the two criteria (age cut off at 65 years plus LDL-
C> 190 or 130mg/dL with LLD) whereas 6% met the “broader”
criteria (age cut off at 65 plus LDL-C> 155 or 115mg/dL with LLD).
Therefore, although these criteria may not seem very specific, they
already enable efficient initial selection.
In the presence of these two criteria, the patient must be
referred for a visit to an FH specialist.3.2.2. Phase 2. “CONFIRM00
The first and the subsequent visits to the “FH specialist/clinic”
aim at confirming an FH diagnosis using DLCN score and/or
deciding whether or not to prescribe confirmatory genetic test. This
may often require more than one visit. We try here to answer some
questions that are often encountered in clinical practice.
Previous history of abnormally high cholesterol levels or LLD(s).
The lifelong persistence of elevated LDL-C (especially
if> 190mg/dL in adults or >130mg/dL before 18 years) or early
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contrast, existence of previously “normal” LDL-C (around average
population level) or elevated triglycerides >200mg/dL may lower
the likelihood of monogenic FH, and rather suggest a polygenic
form of FH (eg. familial combined hyperlipidaemia).
3.2.2.1. Corneal arcus and tendon xanthomas. Detecting these re-
quires some skills when examining the eyes and tendons. Tendon
xanthomas are most often visible in Achilles tendons and more
rarely in extensor tendons of the hands, elbows, heels and knees.
Frequently, they are more palpable (feeling a nodule, or abnormal
thickening) rather than visible. In case of doubt, an increase in
antero-posterior thickness of Achilles tendon (>5,8mm) demon-
strated by echography is suggestive of xanthomas and may rein-
force the probability of FH [17]. Unless the thickening is very high
(>0,9mmm as suggested by Harada-Shiba M et al. [18]), this cannot
replace the criterium ‘tendon xanthomas” in the DLCN score. His-
tory of tendinitis is also indicative, as it occurs more frequently in
FH patients. In interpreting these findings, it is important to
exclude a previous history of tendon surgery, trauma, hyperurice-
mia or other conditions for tendinitis or tendon swelling.
Corneal arcus is more difficult to see on a clear (blue or green)
iris, is often incomplete and/or hidden behind eyelids (it is thus
important to raise eyelids, and instruct patients to look down). It is
only pathognomonic of FH if discovered before the age of 45 years.
However, the finding of a extensive or complete corneal arcus even
at 50 years of age, is indicative of an earlier-onset. Xanthelasmas
(sharply demarcated yellowish collections of cholesterol under-
neath the skin, usually on or around eyelids) are not specific of FH.
3.2.2.2. Family data. History of hypercholesterolaemia in other
members of the family (including children above 4 years) is often
difficult to ascertain. The information that a relative was given a
statin at a younger agemay be of great interest. These points should
ideally be further clarified during the forthcoming visit by asking
the patient to collect more data on his/her relatives.
3.2.2.3. First DLCN assessment and genetic test prescription.
On the basis of the evidence already gathered, the FH specialist can
compute the DLCN score. If> 8, it follows that the patient has FH
with a high level of confidence. In this case, a genetic test is not
necessary but could confirm the diagnosis as well as identify the
molecular defect underlying the dyslipidemia, and may be of help
in subsequent cascade screening (especially to facilitate identifi-
cation of relatives with borderline cholesterol levels, especially in
children). The borderline situation of DLCN between 6 and 8 often
occurs in the absence of tendon xanthomas, corneal arcus <45
years, or LDL-C >330mg/dL. Efforts should primarily be made to
gain additional data (lipid levels in children or tendon echography,
…) that may raise the DLCN score> 8. Otherwise, it is worth in such
situation to ask for a genetic test. For a DLCN score between 3 and 5,
when there are strong suggestive elements to suspect FH, ordering
a genetic analysis may also be justified. There are also situations
where calculation of DLCN score is somewhat compromised and in
which genetic testing may be useful: no known or living relatives
(adoption; parents deceased at a younger age from non-CV causes,
no contact with the family), presence of corneal arcus in a patient
older than 45 years or previous history of local disease on the
tendon.
We developed a tablewith criteria selected for helping clinicians
to decide whether or not to prescribe genetic tests (Table 1).
Supplementary Tables 1 and 2 summarize some of the ethical is-
sues, benefits, indications and cautions regarding genetic testing.
Genetic analysis has a significant cost, is potentially time-
consuming (obtaining results may take 2e5 months), requiresinformed consent of patients on the various ethical issues, and may
identify genetic variations of uncertain significance requiring
additional investigations to confirm/refute causality in hypercho-
lesterolemia. A negative genetic test does not automatically exclude
FH if the DLCN score is high. In previous studies, when patients
were classified on the basis of the DLCN score, 70% of “definite” FH
patients were found to carry a pathogenic variant, only 29% of
“probable” FH and 11% of “possible” FH patients were variant
positive [19].
3.2.3. Phase 3. “EXTEND00
At this stage, a diagnosis of FH can be finalized using all
confirmation data collected (including genetic test if performed). If
the DLCN remains <8 and the genetic test is negative
(Supplementary Tables 1 and 2), the clinician should not neces-
sarily abandon the search. Sometimes, a confirmatory diagnosis
may prove easier to obtain from one relative and the clinician
should make every possible effort to invite some adult relatives to
be examined in search of FH-specific signs (such as corneal arcus in
those <45 years or tendon xanthomas) or children with LDL-C
>190mg/dL (Fig. 2). Such confirmation in other family member(s)
is a good argument to reinforce clinical diagnosis in the index
patient.
3.3. TREAT
3.3.1. Phase 1. “ALERT00
For patients with established CHD, as considered in the pre-
sent paper, initiation of LLD does not really depend upon
confirmation of FH and must be implemented as early and as
intensively as possible in order to achieve target LDL-C level
(<70mg/dL, which in FH patients with very elevated baseline
LDL-C means a LDL-C reduction of 50%) as per current European
guidelines for patients in secondary prevention [12]. This re-
quires prescription of high-intensity statins at the highest-
tolerated dose (atorvastatin 40e80mg, rosuvastatin 20e40mg)
as soon as possible, preferably on first admission day for ACS. If
the patient is already on low- or moderate-intensity statin, a shift
to a high-intensity statin must be considered. If the patient is
already on high-intensity statin, the combination of statin with
ezetimibe should be considered.
3.3.2. Phase 2. “CONFIRM00
Successive visits to the “FH specialist” also have as objective
ensuring drug compliance and adherence, titrating statins and/or
adding other LLD in order to achieve LDL-C <70mg/dL. Often, early
combinationwith ezetimibe is required to achieve an extra 20e25%
LDL-C reduction, far greater than the 6% additional reduction ob-
tained by doubling statin dosage.
3.3.3. Phase 3. “EXTEND00
Even with high-intensity statins combined with ezetimibe,
many FH patients still have elevated LDL-C. Therefore, at this stage,
one may consider the addition of anti-PCSK9 monoclonal anti-
bodies. Alirocumab in the ODYSSEY HIGH FH trial [20,21] and
evolocumab in the RUTHERFORD trial [22] have induced drastic
reductions of LDL-C (40 to 60%) in FH patients on maximally-
tolerated statin (±other LLD), allowing to achieve LDL-C target
(<70mg/dl or <100mg/dl) in the majority of these patients [23].
3.4. Family care
The process of “FAMILY CARE” includes different objectives:
raising awareness of familial predisposition to CVD risk, collecting
data on cholesterol values to calculate DLCN scores and cascade-
Table 1
Probabilities that a genetic test will be positive in various situations where DLCN is 9.
LDL-C (mg/dL) Other findings Probability that genetic test will be positive
330 None (no family data) Very high
250e329 Family (±personal) history but no tendon xanthomas * or corneal arcus before age 45 years ** High
No family data***, with or without personal history and no other findings High
No family (±personal) history and no other findings moderate
190e249 Family (±personal) history but no tendon xanthomas * or corneal arcus before age 45 years ** Moderate
No family data***, with or without personal history and no other findings Moderate
No family (±personal) history and no other findings Low
150e189 Family (±personal) history but no tendon xanthomas * or corneal arcus before age 45 years ** Low
No family data***, with or without personal history and no other findings Low
No family (±personal) history and no other findings Very low
*No tendon xanthomas or presence of tendon swelling but possibly due to other causes than FH.
**Patients is younger than 45 but has no corneal arcus or patients has corneal arcus but is older than 45 years at the moment of the examination.
***No family data may occur for example in the absence of know parents (orphan), if parents and grand-parents died early of other causes, when contact was lost with the
family or in case of small family.
Fig. 2. Algorithm of progression in the diagnostic confirmation (or exclusion) of FH.
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at all stages and they need to be thoroughly motivated.3.4.1. Phase 1.“ALERT00
When a patient suffers from CVD at an early age (<55 years in
men and <60 years in women), it is usually recommended that
family members be screened for lipid- and non-lipid-related CV
risk factors. In this case, it is vital to notify the patient, as soon as
possible, on the existence of a familial predisposition to CVD, so
they may alert relatives on possible CV risk. Conversely, relativesmay provide patient with additional information regarding their
personal histories of hypercholesterolaemia, LLDs, and CVDs, which
may help refining family data. It is however premature, at this
stage, to workmore actively on risk identificationwithin the family.3.4.2. Phase 2. “CONFIRM00
At this phase, still considered exploratory, the “FH specialist”
will essentially try to “confirm” as much as possible the data
regarding family history. At this stage, the patient may be provided
with requests for laboratory testing (total cholesterol, LDL-C, HDL-
Fig. 3. Poster proposed to be displayed in coronary care unit for reminding the alert signs, the name of the “ FH specialist “ to whom the patient should be referred and eventually a
mean to calculate the baseline LDL-C if the patient is under lipid-lowering therapy (without the need of a calculator).
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the patient feels close enough to share his/her health issues. For
results monitoring, the laboratory may be asked to send a copy of
lab results to the relative and his/her GP.
3.4.3. Phase 3. “EXTEND00
Promoting hypercholesterolemia screening in the family must
be donewhatever the final diagnosis. However, if an FH diagnosis is
well established, it must be pursued with all the more stamina,
especially in children. Such family screening must be promoted
through the patient (“FH ambassador”), through the patient's GP,
and GPs (when identified) of relatives, and ideally with a dedicated
nurse.
As first step for FH screening, the panel recommends assess-
ment of routine lipids only, without genetic testing. Based on LDL-C,
it is indeed possible to diagnose FH in adult relatives using the
MEDPED criteria [24,25] or in children using specific diagnostic
criteria [26]. The MEDPED criteria published by Roger William in
1993 (25) can readily be used in Belgium as the distribution of LDL-C
level in general Belgian population (131± 34mg/dl) [27] is almost
identical to that of the general US population (130± 31,4mg/dl).
The diagnosis may be confirmed subsequently using genetic
testing. Having non-elevated LDL-C does not necessarily rule out
the transmission of pathogenic variants to the next generation, as
incomplete penetrance of gene variants may (rarely) occur in FH
[28]. In all cases, the FH specialist must be ready to respond to
queries and requests for advice of screened relatives or to transfer
relevant information to other colleagues if they live in a remote
area.
4. Discussion
The aim of this consensus statement is to achieve a consistent
management strategy for the identification of FH in patients un-
dergoing acute CV events, for the provision of treatment and the
organization of cascade screening in relatives of patients hospital-
ized for CVD in Belgian hospitals. Focusing on ACS, and given that
each year about 10,000 ACS occur in Belgium and given that in the
EUROASPIRE IV study it was estimated that 8% of adults hospital-
ized for ACS have clinical criteria compatible with potential undi-
agnosed FH [17], there is the hope that each year, theremay be up to
800 new FH patients diagnosed in Belgium. More importantly, this
will result in additional FH patients being diagnosed earlier
assuming that cascade screening is adequately performed.
Currently, this strategy is being implemented in most coronary
care units in Belgium. To achieve the successful implementation, a
poster summarizing the strategy was created and distributed to all
the coronary care units in Belgium at the end of 2017 (Fig. 3). Prior
to this, face-to-face meetings with the cardiologists responsible for
the CCU and their colleagues were organized to explain the ratio-
nale of the consensus strategy and the different procedures asso-
ciated with it. We discussed with them the need to designate a well
identified FH specialist, to whom all suspected patients can be
referred for the validation study, we proposed to those specific
centers better equipped with research coordinators to prospec-
tively enter the data of all suspected patients as well as all other
patients in order to collect more precise data on the prevalence of
FH in the CCU and their clinical characteristics.
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